Autosomal Dominant Polycystic Kidney Disease (ADPKD)

1. Clinical Overview

Summary

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the Most Common Inherited Cause of End-Stage Renal Disease (ESRD), affecting approximately 1 in 400-1000 individuals worldwide. It is caused by mutations in PKD1 (85%) or PKD2 (15%) genes encoding Polycystin-1 and Polycystin-2 respectively, which are involved in ciliary signalling, cell proliferation, and fluid secretion. The hallmark is Progressive Development of Multiple Fluid-Filled Cysts in Both Kidneys, leading to massive renal enlargement, destruction of normal parenchyma, and eventual Renal Failure. ESRD typically occurs by 55-60 years (PKD1) or 70-75 years (PKD2). [1,2]

ADPKD is a Systemic Disease with extrarenal manifestations including Hepatic Cysts (Most Common), Intracranial Aneurysms (5-10%), Cardiac Valve Abnormalities, and Colonic Diverticulae. Complications include Hypertension, Chronic Pain, Cyst Infection/Haemorrhage, Nephrolithiasis, and Subarachnoid Haemorrhage. Management focuses on Blood Pressure Control (ACEi/ARB), Hydration, and the vasopressin V2 receptor antagonist Tolvaptan which slows cyst growth and eGFR decline in selected patients. Renal replacement therapy (Dialysis or Transplantation) is required for ESRD. [3,4]

Key Facts

Clinical Pearls

"PKD1 = Earlier, More Severe; PKD2 = Later, Milder": PKD1 mutations cause earlier ESRD.

"Screen Family History of Subarachnoid Haemorrhage": Indicates need for intracranial aneurysm screening.

"Tolvaptan Slows Progression": V2R antagonist reduces cyst growth. Requires liver monitoring.

"Hydration is Key": Suppresses vasopressin and cyst growth.

"Cyst Infection Often Gram-Negative": Fluoroquinolones penetrate cysts well.

"Think of the Liver Too": Hepatic cysts present in Greater than 80% - Especially severe in women.

"Avoid NSAIDs": Nephrotoxic and can accelerate CKD progression.

"TKV Predicts Progression": Total Kidney Volume (MRI) is key for risk stratification (Mayo Classification).

"Mayo 1C-1E = Tolvaptan Candidates": Higher classes indicate rapid progressors who benefit from treatment.

"50% Inheritance Risk": Key for family counselling - Each child has 50% chance.

Why This Matters Clinically

ADPKD is the fourth leading cause of ESRD globally and accounts for 5-10% of all patients requiring renal replacement therapy. It affects multiple generations of families with significant psychological and socioeconomic impact. The availability of disease-modifying therapy (Tolvaptan) has changed management algorithms, making early diagnosis and risk stratification crucial. Identification of patients at risk of intracranial aneurysm rupture is life-saving. ADPKD is frequently examined due to its genetic basis, systemic manifestations, and evolving treatment options.

---

2. Epidemiology

Global Burden

Incidence & Prevalence by Population

Demographics

Gene-Phenotype Correlation - Detailed

Risk Factors for Rapid Progression

Age-Related Milestones

Healthcare Burden

---

3. Genetics and Pathophysiology

Genetics

Inheritance:

• Autosomal Dominant
• Each child of affected parent has 50% risk
• Variable expressivity within families
• ~10% de novo mutations

Molecular Mechanism:

• PC1 and PC2 form a receptor-channel complex
• Located in primary cilia, plasma membrane, ER
• Sense fluid flow and regulate intracellular calcium
• Loss of function leads to dysregulated cell signalling [5,6]

Pathophysiology

Step 1: "Two-Hit" Hypothesis

• First hit: Germline mutation (Inherited – All cells carry one mutant allele)
• Second hit: Somatic mutation in other allele (Random event in individual tubular cells)
• Explains focal cyst development (Only cells with both hits form cysts)
• Accounts for variable severity and asymmetric cyst distribution [7]

Step 2: Cellular Changes in Cyst Formation

• Loss of functional polycystin → Decreased intracellular calcium
• Increased cAMP (Cyclic AMP) levels
• Activation of CFTR chloride channels → Fluid secretion into cyst lumen
• Increased Cell Proliferation (mTOR pathway activation)
• Increased Vasopressin V2 receptor signalling [8,9]

Step 3: Cyst Growth

• Fluid accumulates in cyst lumen (Secretion)
• Cyst walls proliferate
• Cysts detach from tubules and enlarge autonomously
• Compression of adjacent parenchyma
• Gradual destruction of normal nephrons

Step 4: Progressive Kidney Enlargement

• Total Kidney Volume (TKV) increases exponentially
• Normal kidney ~150-200 mL → ADPKD can exceed 2-3 Litres
• TKV predicts rate of eGFR decline
• Kidneys palpable in advanced disease [10]

Step 5: Renal Function Decline

• eGFR remains stable initially despite increasing TKV
• Once ~50% nephrons lost, eGFR declines
• Typical decline ~4-5 mL/min/year
• ESRD: PKD1 ~55-60 yrs, PKD2 ~70-75 yrs

Additional Pathophysiological Mechanisms:

Vascular Dysfunction:

• Endothelial dysfunction occurs early
• Nitric oxide availability reduced
• Contributes to hypertension
• Increased cardiovascular risk

Inflammation and Fibrosis:

• Chronic low-grade inflammation
• Cytokine release (IL-1β, TNF-α)
• Progressive tubulointerstitial fibrosis
• Contributes to nephron loss

Metabolic Derangements:

• Abnormal glucose metabolism in cyst epithelium
• Increased glycolysis (Warburg effect)
• Aerobic glycolysis drives cyst growth
• Potential therapeutic target

Pathophysiology Diagram

Image

Risk Prediction: Mayo Classification

Higher class = Candidate for Tolvaptan therapy [11]

---

4. Clinical Presentation

Key Principle

[!NOTE] ADPKD is often asymptomatic for decades. Many patients present with incidental imaging findings or through family screening. Hypertension is typically the first clinical sign, often preceding overt renal dysfunction by years.

Renal Manifestations - Detailed

Hypertension:

Pathogenesis of Hypertension in ADPKD:

• Intrarenal ischaemia from cyst compression
• Activation of renin-angiotensin-aldosterone system (RAAS)
• Decreased nitric oxide bioavailability
• Increased sympathetic nervous system activity
• Sodium retention and volume expansion
• Vascular stiffness and arterial wall changes [12]

Flank/Abdominal Pain:

Gross Haematuria:

Nephrolithiasis:

Cyst Infection:

Clinical Distinction - Cyst vs UTI Infection:

Renal Manifestations Summary Table

Extrarenal Manifestations - Detailed

Hepatic Cysts (Polycystic Liver Disease - PLD):

Mechanisms of Severe PLD in Women:

• Oestrogen promotes cyst growth
• Pregnancy-related hormonal changes
• Multiple pregnancies cumulative effect
• Post-menopausal HRT may worsen
• Oral contraceptive pills may accelerate growth

Intracranial Aneurysms:

Risk Factors for Aneurysm Rupture:

• Size greater than 7mm
• Posterior circulation location
• Family history of rupture
• Hypertension (uncontrolled)
• Smoking
• Female sex
• Multiple aneurysms

Cardiac Manifestations:

Other Extrarenal Features:

Red Flags

[!CAUTION] Red Flags – Immediate Action Required:

• Sudden severe headache ("Worst headache of life") → Subarachnoid haemorrhage - Call 999/Emergency CT
• Fever + Flank pain + Raised inflammatory markers → Cyst infection - Antibiotics + Consider imaging
• Severe flank pain + Haematuria → Cyst haemorrhage/Rupture - Supportive care
• Gross haematuria with clots → Cyst bleed, Stone, or rarely malignancy
• Severe hypertension (Greater than 180/110) → Aggressive BP control
• Sudden onset abdominal pain with hypotension → Ruptured cyst/Internal bleeding

Symptom Progression by Age

---

5. Clinical Examination

Key Principle

[!NOTE] ADPKD examination is often unremarkable in early disease. Key findings become apparent as disease progresses. Always check blood pressure as this is often the first detectable abnormality.

Structured Approach for OSCE/Clinical

Introduction and Consent:

• Introduce yourself, Explain examination, Obtain consent
• Position patient supine at 45°, Adequately exposed (Abdomen visible)

General Inspection:

Hands:

Cardiovascular:

Abdominal Examination - Detailed:

Kidney Palpation Technique:

Key Examination Findings:

Signs of CKD to Look For:

Documentation Checklist

What to Present in Viva/OSCE

"On examination, this patient appears well. Blood pressure is elevated at [X/Y]. On abdominal examination, there are bilateral ballotable renal masses with an irregular surface, consistent with polycystic kidneys. There is also hepatomegaly. I note an umbilical hernia. There are no signs of advanced CKD. The findings are consistent with ADPKD."

---

6. Investigations

Key Principle

[!NOTE] In ADPKD, investigations serve to:

1. Confirm diagnosis (Imaging + Family history)
2. Assess progression (TKV, eGFR)
3. Identify complications
4. Determine treatment eligibility (Tolvaptan)

Diagnostic Imaging

Ultrasound (First-Line):

Sensitivity increases with age. May miss early disease in young at-risk individuals. [13]

Ultrasound Findings:

MRI:

MRI Mayo Classification:

CT Scan:

Laboratory Investigations

Routine Monitoring:

Investigations for Complications:

Genetic Testing

Indications:

What Genetic Testing Provides:

Screening for Complications

Investigations Summary by Stage

---

7. Management

Management Algorithm

Image

Key Principle

[!IMPORTANT] ADPKD is a SYSTEMIC disease requiring LIFELONG management:

• Blood pressure control is the cornerstone
• Disease-modifying therapy (Tolvaptan) for rapid progressors
• Complication management
• Family screening and genetic counselling
• Renal replacement therapy planning

Blood Pressure Control - Detailed

Evidence Base:

• HALT-PKD Trial showed rigorous BP control (Less than 110/75) slowed TKV growth in CKD 1-2 [14]

Target:

First-Line Agents:

Add-On Agents (If ACEi/ARB Not Sufficient):

AVOID:

• ❌ Dual ACEi + ARB (HALT-PKD showed no benefit and more side effects)

Disease-Modifying Therapy: Tolvaptan - Detailed Protocol

Mechanism: Vasopressin V2 receptor antagonist → Reduces cAMP in cyst epithelium → Slows cyst proliferation and fluid secretion → Slows TKV growth → Slows eGFR decline

Key Trials:

[15,16]

NICE TA873 (2023) Indications for Tolvaptan:

Dosing Schedule:

Split dosing reduces nocturnal polyuria

Monitoring Protocol:

Side Effects and Management:

Contraindications:

Lifestyle and Conservative Management

Management of Complications - Detailed

Cyst Pain Management:

Cyst Infection Protocol:

Cyst Haemorrhage:

Nephrolithiasis:

Polycystic Liver Disease:

Renal Replacement Therapy

Intracranial Aneurysm Screening

Emerging and Future Therapies

Novel Therapeutic Targets:

---

8. Complications

Overview

Renal Complications - Detailed

Hypertension:

Cyst Pain:

Cyst Infection:

Cyst Haemorrhage:

Nephrolithiasis:

CKD and ESRD:

Extrarenal Complications - Detailed

Polycystic Liver Disease (PLD):

Intracranial Aneurysms:

Cardiac Complications:

Gastrointestinal Complications:

Complications Summary Table

---

9. Prognosis & Outcomes

Progression to ESRD

Predictors of Rapid Progression

Prognosis After RRT

Long-Term Outcomes with Tolvaptan

Projected Delay in ESRD:

• TEMPO 3:4 and REPRISE data suggest tolvaptan may delay ESRD by 6-8 years in rapid progressors
• Earlier initiation may provide greater cumulative benefit
• Long-term adherence critical for sustained benefit

---

10. Evidence & Guidelines

Key Guidelines

[17,18]

Landmark Trials - Detailed

HALT-PKD Trial (2014)

TEMPO 3:4 Trial (2012)

REPRISE Trial (2017)

Evidence Strength Summary

---

11. Patient/Layperson Explanation

What is ADPKD?

ADPKD (Autosomal Dominant Polycystic Kidney Disease) is an inherited condition where fluid-filled cysts grow in your kidneys. Over time, these cysts get bigger and more numerous, and the kidneys can become very large - sometimes as big as a rugby ball.

Key Points to Understand

Why Does it Happen?

It's caused by a gene change (mutation) that you inherit from a parent. If one of your parents has ADPKD, you have a 50% chance of inheriting it. In about 10% of cases, it appears "out of the blue" with no family history (new mutation).

The Two Genes:

• PKD1 (85% of cases) – Tends to cause earlier kidney problems (around 55-60 years)
• PKD2 (15% of cases) – Usually milder, with later kidney problems (around 70-75 years)

What are the Symptoms?

Many people have no symptoms for years. Common symptoms include:

What Other Problems Can it Cause?

ADPKD can affect other parts of your body too:

Will My Kidneys Fail?

Eventually, many people with ADPKD will need dialysis or a kidney transplant. This typically happens:

• Around age 55-60 for PKD1 gene
• Around age 70-75 for PKD2 gene

BUT: This is NOT inevitable for everyone. Many things can slow progression.

What I Can Do to Help My Kidneys

What Treatment is Available?

What is Tolvaptan?

Tolvaptan is a relatively new medication that can slow down cyst growth and kidney decline. It's not for everyone - you need to be assessed to see if it's suitable.

Should My Family be Tested?

Yes. First-degree relatives (children, siblings, parents) should be offered screening.

When to Worry / See a Doctor Urgently

[!CAUTION] See a doctor urgently if you have:

• Severe sudden headache ("worst headache ever") – could be a brain bleed
• High fever with flank pain – could be cyst infection
• Heavy blood in urine with clots
• Very high blood pressure (greater than 180/110)
• Feeling very unwell

Frequently Asked Questions (FAQs)

Psychological Impact and Support

Living with ADPKD can be challenging:

Support Resources:

• PKD Charity (UK): www.pkdcharity.org.uk
• Kidney Care UK: www.kidneycareuk.org
• PKD Foundation (US): www.pkdcure.org

---

12. References

Primary Guidelines

1. Chapman AB, et al. KDIGO Cyst Controversy Conference on ADPKD. Kidney Int. 2015;88(1):17-27. PMID: 25786098

2. Gansevoort RT, et al. Recommendations for the use of tolvaptan in ADPKD: EKA/ERA-EDTA position statement. Nephrol Dial Transplant. 2022;37(12):2303-2316. PMID: 36054816

3. NICE Technology Appraisal TA873. Tolvaptan for treating ADPKD. NICE. 2023.

4. Chebib FT, Torres VE. ADPKD: Core curriculum 2016. Am J Kidney Dis. 2016;67(5):792-810. PMID: 26786631

Genetics and Pathophysiology

5. Harris PC, Torres VE. Genetic mechanisms and signaling pathways in ADPKD. J Clin Invest. 2014;124(6):2315-2324. PMID: 24892705

6. Cornec-Le Gall E, et al. PKD1 and PKD2 mutations in ADPKD. J Am Soc Nephrol. 2013;24(6):1006-1013. PMID: 23431072

7. Ong ACM, Harris PC. A polycystin-centric view of cyst formation and disease. Nat Rev Nephrol. 2015;11(7):395-405. PMID: 25826034

8. Torres VE, Harris PC. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol. 2006;2(1):40-55. PMID: 16932388

9. Wallace DP. Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta. 2011;1812(10):1291-1300. PMID: 21118718

Diagnosis and Imaging

10. Irazabal MV, et al. Mayo Classification (HtTKV) for ADPKD. J Am Soc Nephrol. 2015;26(1):160-172. PMID: 25060052

11. Perrone RD, et al. Total kidney volume is a prognostic biomarker in ADPKD. Clin J Am Soc Nephrol. 2017;12(12):2059-2067. PMID: 29074820

12. Pei Y, et al. Unified criteria for diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205-212. PMID: 18945943

Hypertension Management

13. Chapman AB, et al. Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010;17(2):153-163. PMID: 20219619

Landmark Trials

14. Schrier RW, et al. Blood pressure in early ADPKD (HALT-PKD). N Engl J Med. 2014;371(24):2255-2266. PMID: 25399733

15. Torres VE, et al. Tolvaptan in patients with ADPKD (TEMPO 3:4). N Engl J Med. 2012;367(25):2407-2418. PMID: 23121377

16. Torres VE, et al. Tolvaptan in later-stage ADPKD (REPRISE). N Engl J Med. 2017;377(20):1930-1942. PMID: 29105594

Guidelines and Reviews

17. Gansevoort RT, et al. Recommendations for the use of tolvaptan in ADPKD. Nephrol Dial Transplant. 2016;31(3):337-348. PMID: 26908832

18. Bergmann C, et al. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4(1):50. PMID: 30523303

Extrarenal Manifestations

19. Müller RU, Bhutani V. Extrarenal manifestations of ADPKD. Curr Opin Nephrol Hypertens. 2020;29(2):243-249. PMID: 31834119

20. Soroka S, et al. Intracranial aneurysms in ADPKD. Kidney Int. 2013;84(5):903-916. PMID: 23783241

---

13. Examination Focus

High-Yield Facts for Exams

Common Exam Questions

Short Answer Questions:

1. Genetics Question: "A 30-year-old woman has ADPKD. What is her child's risk of inheriting the condition?"

   • Answer: 50% (Autosomal dominant inheritance).

2. Diagnostic Criteria: "How many cysts are required for diagnosis in a 45-year-old at-risk individual?"

   • Answer: ≥2 cysts in each kidney (Ravine criteria for 40-59 years).

3. Management Question: "What is the first-line antihypertensive in ADPKD?"

   • Answer: ACE inhibitor or ARB (RAAS inhibition).

4. Disease-Modifying Therapy: "What medication slows disease progression in ADPKD?"

   • Answer: Tolvaptan (Vasopressin V2 receptor antagonist).

5. Screening Question: "Which patients with ADPKD should be screened for intracranial aneurysms?"

   • Answer: Family history of SAH/aneurysm, high-risk occupation, pre-major surgery, symptoms.

OSCE Scenarios:

Scenario 1: History Taking "Take a history from this 35-year-old patient presenting with hypertension and a family history of kidney disease."

Key Points to Cover:

• Symptoms: Pain, haematuria, UTIs
• Family history: ADPKD in relatives, SAH
• Past medical history: Hypertension, CKD
• Impact: Work, pregnancy plans
• Concerns: Inheritance, prognosis

Scenario 2: Examination "Examine this patient's abdomen."

Expected Findings:

• Bilateral ballotable renal masses
• Irregular/nodular surface
• Hepatomegaly (if PLD)
• Hernias (umbilical/inguinal)

Scenario 3: Counselling "Counsel this patient about tolvaptan therapy."

Key Points:

• Mechanism: Blocks vasopressin, slows cyst growth
• Benefits: Slows eGFR decline, delays ESRD
• Side effects: Polyuria, nocturia, thirst
• Monitoring: Monthly LFTs for 18 months
• Expectations: Not a cure, requires adherence

MCQ Practice:

Question 1: Which gene mutation causes the more severe phenotype in ADPKD?

• A) PKD2
• B) PKD1
• C) Both equal
• D) Neither

Answer: B) PKD1 (Earlier ESRD, more severe disease)

Question 2: What is the mechanism of action of tolvaptan?

• A) ACE inhibition
• B) mTOR inhibition
• C) Vasopressin V2 receptor antagonism
• D) CFTR inhibition

Answer: C) Vasopressin V2 receptor antagonism

Question 3: What is the most common extrarenal manifestation of ADPKD?

• A) Intracranial aneurysm
• B) Hepatic cysts
• C) Mitral valve prolapse
• D) Colonic diverticula

Answer: B) Hepatic cysts (Greater than 80% by age 60)

Viva Questions and Model Answers

Q: What is the genetic basis of ADPKD?

A: ADPKD is an autosomal dominant condition caused by mutations in PKD1 (85%, chromosome 16) or PKD2 (15%, chromosome 4). These encode polycystin-1 and polycystin-2 respectively, which form a receptor-channel complex involved in calcium signalling and ciliary function. The disease follows a two-hit hypothesis where a germline mutation is inherited, and a second somatic mutation leads to focal cyst development. PKD1 mutations cause more severe disease with ESRD around 55-60 years, while PKD2 is milder with ESRD around 70-75 years.

Q: How would you manage hypertension in a 30-year-old with ADPKD?

A: I would target rigorous blood pressure control based on HALT-PKD trial evidence. For this young patient with early disease, I would aim for less than 110/75 mmHg if tolerated. First-line therapy would be an ACE inhibitor (e.g., ramipril) or ARB (e.g., losartan) for RAAS blockade and nephroprotection. I would NOT use dual ACEi+ARB as HALT-PKD showed no benefit and increased side effects. If BP not controlled, I would add a calcium channel blocker. I would also emphasize lifestyle measures: salt restriction (less than 6g/day), hydration (3-4L/day), weight management, smoking cessation, and avoiding NSAIDs.

Q: Which patients with ADPKD should receive tolvaptan?

A: Based on NICE TA873 criteria, tolvaptan is indicated for patients with confirmed ADPKD, CKD stage 2-3 (eGFR 30-89), and evidence of rapid progression. Rapid progression is defined as Mayo class 1C-1E (TKV growth greater than 3%/year) or TKV greater than 750mL. Contraindications include liver disease, inability to drink adequately, pregnancy, and breastfeeding. The evidence comes from TEMPO 3:4 and REPRISE trials showing tolvaptan reduces TKV growth by 49% and slows eGFR decline. Monitoring requires monthly LFTs for 18 months to detect hepatotoxicity, which occurs in 1-2% of patients.

Q: What are the indications for intracranial aneurysm screening in ADPKD?

A: I would screen patients with: (1) Family history of SAH or intracranial aneurysm (risk increases to 20%), (2) High-risk occupations such as pilots or professional drivers, (3) Prior to major surgery especially cardiac surgery, (4) Symptoms such as new or severe headaches or neurological signs, and (5) Patient anxiety/request after informed discussion. The screening modality is MRA (non-invasive). If negative, repeat every 5 years. If an aneurysm is found, frequency increases to 6-12 monthly and neurosurgical referral is needed, particularly if greater than 5-7mm or symptomatic.

Q: What are the key complications of ADPKD and their management?

A: Key renal complications include hypertension (60-80%, manage with ACEi/ARB targeting less than 130/80), cyst infection (30-50%, treat with fluoroquinolones for 4-6 weeks as they penetrate cysts), cyst haemorrhage (30-50%, usually conservative with bed rest and hydration), nephrolithiasis (20-30%, manage with hydration and citrate supplementation), and progressive CKD to ESRD (greater than 50%, requiring RRT planning). Extrarenal complications include polycystic liver disease (greater than 80%, especially in women with oestrogen exposure), intracranial aneurysms (5-10%, screen high-risk patients with MRA), cardiac valve abnormalities especially mitral valve prolapse (25%), and increased risk of hernias and diverticulae. Management requires a multidisciplinary approach addressing all manifestations.

---